The case in front of me: AST · ALT · mazdutide.
The comparison I want does not seem to exist anywhere in a form I can evaluate.
I have read the arguments for each and they do not engage with each other.
Which axes does this decision turn on?
The case in front of me: AST · ALT · mazdutide.
The comparison I want does not seem to exist anywhere in a form I can evaluate.
I have read the arguments for each and they do not engage with each other.
Which axes does this decision turn on?
Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
| Quantity | Value | Derivation |
|---|---|---|
| Control-arm event rate | 8.0 % | From the trial table, not the abstract |
| Hazard ratio | 0.80 | Reported |
| Treated event rate | 6.4 % | 8.0 × 0.80 |
| Absolute risk reduction | 1.6 pp | 8.0 − 6.4 |
| Number needed to treat | 63 | 1 ÷ 0.016 |
| Relative risk reduction | 20 % | 1 − 0.80 |
The last two rows describe the same finding. Only one of them is used in headlines.
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.
Keep the full report, not the number. You will need the units and the interval later.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThe relevant statistical point is that a ninety-five per cent reference interval means one analyte in twenty will read out of range in a healthy person by construction.
A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
This is answerable, and the answer is mostly about which tests rather than how many.
Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
In practice, haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
edited 24 Apr 2025 by bufferline42 — clarified the distinction between purity and content
Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
Decide the action for each result before you order the test.
Before reacting to any single value, check whether it is outside the interval by an amount larger than the assay's own variation.
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.